CompletedNot Applicable

Secukinumab (Cosentyx®) Effectiveness in Axial Spondyloarthritis and Psoriatic Arthritis Patients Using Artificial Intelligence (SpAINET): Spanish Multicenter, Retrospective, Real World Evidence Study

Spain758 participantsStarted 2021-06-02

Plain-language summary

This was a multicenter, retrospective, and non-interventional study using secondary data captured in the Electronic Health Records (EHRs). The extraction of the data captured in the EHRs was performed with EHRead® by SAVANA, an innovating data-driven system based on Natural Language Processing (NLP) and big data analytics. Data was extracted and analyzed at Index Date, Follow Up, or as specified for each variable.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Aged ≥ 18 years. * Diagnosed with axSpA or PsA. * Had received or are receiving bDMARD, independently of the line of treatment, from January 2018 to data collection. * Had at least 3 months follow up from first bDMARD administration. * Patients with EHRs. Exclusion Criteria: • Receiving bDMARD within a clinical trial from January 2018 to data collection.

What they're measuring

Proportion of patients achieving disease control status at 6 months (±3 months) of secukinumab treatment

Timeframe: month 6

Trial details

NCT IDNCT05677542

SponsorNovartis Pharmaceuticals

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2021-12-31

View on ClinicalTrials.gov More Axial Spondyloarthritis trials